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Design of clinical antiepileptic drug trials 
COLIN D. BINNIE 
Department of Clinical Neurophysiology, Maudsley Hospital, London, UK 
It may fairly be claimed that up to the last decade no antiepileptic drug (AED) had undergone rigorous testing. 
The development programmes of the new AEDs registered in recent years have necessarily been innovative, 
and methods of AED testing are still undergoing rapid evolutionary change. Clinical evaluation of AEDs is 
both difficult and complex, due mainly to two factors: (1) intermittence of clinical events, which means that 
dosing for periods of several weeks is generally necessary, leading to problems of poor compliance and inaccur- 
ate reporting of events by carers and patients; and (2) therapeutic necessity, which means that it is, in general, 
unacceptable to withhold effective treatment from a person with epilepsy. Consequently monotherapy, either 
with a trial drug or with placebo, can rarely be justified. In consequence most phase II trials use add-on therapy 
which in turn causes various problems. Conventional phase II AED trials are usually placebo-controlled a d- 
on studies employing either a parallel or crossover design. The latter is subject o a number of practical and 
theoretical objections, notably on grounds of carry-over and order effects. Increasing attention has recently 
been directed to ethically acceptable monotherapy designs. One approach first exploited in the development of 
felbamate is the performance of monotherapy trials in patients whose AEDs have been withdrawn as part of a 
preoperative assessment protocol. Other possibilities for achieving monotherapy are also discussed. 
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INTRODUCTION 
It may fairly be claimed that up to the last 
decade no antiepileptic drug (AED) had under- 
gone rigorous testing. Coatsworth 1 in a com- 
prehensive review of AED assessment, re- 
ported three controlled trials up to that date, 
and by 1976 Richens was able to identify some 
172. Gram et al 3 found 51 by 1982, but the 
majority suffered gross methodological de- 
ficiences. In the same year, on being asked to 
give a talk on the efficacy of the most recently 
registered AED, clonazepam, I was embar- 
rassed to discover that of 210 efficacy studies, 
only six were controlled, and those so gravely 
flawed as to be uninterpretable 4. In the past 
decade the situation has changed ramatically, 
the number of controlled AED trials currently 
in progress must exceed the total of those com- 
pleted before 1983. The development pro- 
grammes of the new AEDs registered in recent 
years have necessarily been innovative, and 
methods of AED testing are still undergoing 
rapid evolutionary change. 
WHY AEDS ARE HARD TO TEST 
Clinical evaluation of AEDs is both difficult 
and complex, due mainly to two factors: inter- 
mittence of clinical events and therapeutic 
necessity. 
Intermittence of clinical events 
The clinical manifestations of epilepsy are 
intermittent, and prolonged study is therefore 
necessary to demonstrate efficacy. Except in 
the case of those types of seizures that occur 
many times daily (as absences), this generally 
demands that dosing continues for periods of 
several weeks. This requirement leads to other 
problems. 
1. Prolonged toxicological studies must be 
completed prior to phase II investigations. 
2. Unless the subjects are so disabled as to re- 
quire hospitalization on clinical grounds 
(not an ideal group for demonstrating effi- 
cacy), studies will be performed in out- 
patients without close supervision. This in 
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turn creates or exacerbates other difficulties 
(3-5 below). 
3. Seizure frequency cannot be conveniently 
determined by intensive monitoring but 
relies on reporting by patients or carers. 
4. During prolonged administration there is a 
heightened risk of non-compliance. 
5. Reporting of adverse experiences in out- 
patients may be dangerously delayed, 
incomplete, or unreliable. 
Therapeutic necessity 
It is, in general, unacceptable to withhold ef- 
fective treatment from a person with epilepsy. 
Monotherapy either with a trial drug or with 
placebo can therefore be justified only under 
special circumstances ( ee below). In conse- 
quence, most phase II trials use add-on therapy 
which in turn causes various other problems. 
1. Drug interactions may confound both thera- 
peutic and adverse effects. Elevation of 
blood levels of co-medication may cause in- 
toxication, which may be wrongly attri- 
buted to the experimental gent, may break 
the blinding, or indeed lead to abandonment 
of the trial. The difficulties are well illus- 
trated by recent trials of the imidazoles, 
nafimidone and denzimol 5,s. Converseley, 
efficacy may be wrongly ascribed to a new 
product because it causes an increase in con- 
centrations of co-medication; thus sul- 
thiame probably owed most of its apparent 
antiepileptic action to elevation of pheny- 
toin levels 7. 
Conversely, induction of metabolism of 
the co-medication could produce lower than 
expected blood levels and result in a failure 
to demonstrate any beneficial effect of the 
experimental drug. 
Difficulties in blinded dosing of the exper- 
imental drug itself will arise if its metab- 
olism is influenced by the co-medication, as 
is well illustrated in the case of lamotrigine 
which has a reduced half-life in patients 
taking enzyme inducers, such as carbama- 
zepine, and a greatly delayed metabolism in 
those on valproate monotherapy s. 
Such problems are not insuperable, but 
require some special precautions tobe taken 
in trial design. For instance, in an add-on 
study of felbamate, Leppik et al 9, knowing 
the trial drug reduced clearance of pheny- 




used an unblinded monitor to adjust dosage 
so as to keep concentrations of the co- 
medication at baseline values. Conversely, 
Binnie et all° compensated for the effects of 
co-medication on lamotrigine metabolism, 
again by the use of an unblinded investi- 
gator who calculated lamotrigine half-lives 
from observations in the first week of dosing 
and individualized each patient's regime 
thereafter. 
Pharmacokinetic interactions apart, any 
demonstrated efficacy or adverse effects 
may depend on a pharmacodynamic synergy 
with the co-medication. 
The population studied is necessarily drug 
resistant and a product of great potential 
value (due, for instance, to exceptional 
tolerability or favourable pharmacokin- 
etics) may show no effect and be rejected. 
Registration is likely to be granted only for 
the indication tested, which may address 
only that 20% of the potential AED market 
represented by people resistant o existing 
drugs. 
CONVENTIONAL TRIAL DESIGNS 
Conventional phase II AED trials are usually 
placebo-controlled, add-on studies employing 
either a single period parallel group ('parallel') 
or multiple periods within patients ('crossover') 
design. Theoretical considerations favour the 
parallel design as the crossover has many dis- 
advantages. 
1. In practice, crossover trials typically 
involve two 3-month treatment periods (Fig. 
1); one on placebo, the other on the test sub- 
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Fig. 1: Two periods within patients 'crossover' design. 
stance. A baseline period is required to 
establish stability of dosing with co- 
medication, seizure documentation, etc. 
possibly a further 8 weeks. A washout 
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period is required between phases I and II 
for withdrawal of the drug from those 
patients receiving it in phase I. The 
duration of this washout depends on the 
known pharmacokinetic and dynamic 
properties of the substance; it must be long 
enough to allow gradual dose reduction to 
minimize the risk of withdrawal seizures. If 
the drug is believed to have a prolonged 
action it is desirable that sufficient time 
should elapse for this to have ended before 
phase II. Four weeks would be a typical 
duration for this period. A further washout 
will be required for withdrawal after phase 
II. It will be seen that in a typical crossover 
AED trial each patient will be required to 
participate for some 40 weeks. Dropouts due 
to withdrawal of consent, non-compliance, 
or intercurrent life events may therefore 
present a major problem in crossover trials. 
2. Even after precautions have been taken, by 
the use of apparently adequate baseline and 
washout periods, carry-over and order 
effects may occur. If the test drug has an 
action more prolonged than supposed, or 
indeed produces a lasting change in epi- 
lepsy, it may be found that seizure counts on 
placebo are greater in those subjects who do 
not receive active drug until phase II and 
less in those who take placebo in phase II, 
having had the verum in phase I. 
Admission criteria usually include a 
minimum seizure frequency. Patients with 
unstable pilepsy may meet he criteria and 
be recruited uring a period in which their 
seizures are more than usually frequent. 
Over subsequent months there will there- 
fore be a tendency for this selected group to 
show a regression towards their habitual 
mean seizure frequency, with a progressive 
reduction in seizures from baseline, through 
phase I and into phase II. Thus the active 
drug may appear more efficacious in phase 
II than in phase I. 
Sound design, notably the use of adequate 
baseline and washout periods, may help to 
reduce both carryover and treatment/period 
effects. If they nevertheless occur, appropri- 
ate statistical methods are available, but 
these are generally regarded as a last resort 
to salvage an otherwise uninterpretable 
trial. 
3. Ethical difficulties may arise if patients 
show a clinically important reduction in 
seizures during phase I. It may then be con- 




may refuse) to change to the alternative, 
presumed placebo treatment for phase II. 
Attempts to avoid this dilemma by use of a 
single-blind design, giving placebo to all 
patients in phase I, is not a satisfactory 
solution due to the problem of possible spon- 
taneous progressive seizure reduction over 
the course of the trial, as noted above. 
Perhaps the most compelling practical argu- 
ment against crossover trials is the prefer- 
ence expressed by some regulatory bodies 
for other designs. 
Parallel designs may be the only possibility 
in situations where the clinical state of the 
patient is rapidly changing, for instance 
studies of status epilepticus, and the pre- 
surgical withdrawal trials considered 
below. 
Notwithstanding the above, crossover 
designs continue to be widely used. Patients 
with epilepsy show great inter-subject 
variability and several factors are known to 
affect prognosis. It is therefore difficult to 
obtain suitably matched groups for parallel 
trials and it is necessary to rely on the 
investigation of sufficient numbers of 
patients for effects of relevant inter-subject 
differences to be overcome by appropriate 
statistical analysis. Within patients, cross- 
over trials give greater power: if all subjects 
responded to a trial drug, one could achieve 
the 5% level of significance by the sign test 
with only seven patients. In general it is 
estimated that a parallel design will require 
three to six times more subjects to achieve 
power eqivalent to that of a crossover trial. 
With increasing numbers of new AEDs cur- 
rently undergoing clinical testing, recruit- 
ment of suitable patients at sites with 
research expertise in epilepsy is becoming 
difficult. Sufficient subjects for a parallel 
design may often be obtainable only by 
resorting to a multicentre trial, which leads 
in turn to other difficulties arising from 
differences in patient populations or in 
clinical practice between the different 
centres. In practice, the power of the cross- 
over design may be an overriding consider- 
ation in planning drug development. 
ALTERNATIVE  TR IAL  DES IGNS 
Several variants on traditional designs are 
available. They are often complex and interac- 
tive and may be under-used because of per- 
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Fig. 2: Response conditional crossover design: patients finish taking that treatment o which they first responded, or as non- 
responders having had a trial of both treatments. No patient experiences withdrawal of a treatment which appears effective. 
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Fig. 3: Enriched parallel design: trial drug is introduced under open conditions, dose can be escalated to response or tolerance; 
co-medication can be adjusted if there are interactions. Admission of non-responders to the controlled trial is avoided, use of 
placebo is minimized, power of controlled trial maximized. 
ceived difficulties in their administration. In a 
response-conditional crossover design (Fig. 2), 
patients are randomized to an initial treat- 
ment, either active or placebo, and remain on 
this if there is a specified reduction in seizure 
frequency with respect to baseline. This 
approach avoids the ethical problem of trans- 
ferring patients from treatment to which they 
have apparently responded. If the trial drug is 
highly efficacious in the test population, the 
number of patients receiving placebo will be 
greatly reduced, potentially halved. 
Reduction of exposure to placebo is also 
achieved by an enriched parallel design (Fig. 
3). Here the patients commence add-on treat- 
ment with the trial drug under open-label con- 
ditions. This permits adverse effects to be 
closely monitored and the dose to be escalated 
until seizure control is achieved, or to the 
limits of tolerance. In patients who apparently 
respond, the dose is optimized and they then 
enter a double-blind controlled phase in which 
they are randomized either to placebo r to con- 
tinuation of the active substance. Provided 
withdrawal seizures can be avoided, which will 
give a spurious advantage to the active drug in 
the randomized phase, this method offers the 
advantages of a parallel design but with in- 
creased power, as only subjects who apparently 
respond enter the controlled phase. The advan- 
tages of dose optimization under open con- 
ditions are considerable if there are problems 
of drug interactions or uncertainty about the 
therapeutic range. 
MONOTHERAPY TR IALS  
Increasing attention has recently been directed 
to ethically acceptable monotherapy designs. 
One approach, first adopted by Bourgeois et 
a111, in the development of felbamate is the 
performance ofmonotherapy trials in patients 
whose AEDs have been withdrawn to facilitate 
capture of seizures by telemetry, as part of a 
preoperative assessment protocol. Seizure 
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count was lower on felbamate than placebo (P 
< 0.028) and only 46% of patients uffered four 
seizures within 28 days on felbamate, whereas 
88% did so on placebo (P < 0.001). 
The conduct of such trials is difficult and 
complex. The patients are in an unstable state 
and there may be only a brief interval between 
capturing sufficient seizures to meet the needs 
of preoperative assessment and the onset of 
serial seizures demanding immediate control. 
To be of demonstrable efficacy under these cir- 
cumstances the test drug must act swiftly. If 
the half-life is long or efficacy depends on an 
active metabolite and several days are 
required to build up a therapeutic oncen- 
tration, the opportunity to prove an effect may 
be missed. In many patients it may be imposs- 
ible to achieve monotherapy if seizure fre- 
quency increases rapidly before the existing 
medication is fully withdrawn (as was the case 
in the study of Bourgeois et all1). Variants of 
this design have been used by the author, for 
an open trial of remacemide 12, and for a con- 
trolled trial of tiagabine, in which the test 
treatments were introduced prior to with- 
drawal of other medication. This last approach 
may avoid many of the difficulties described 
above, but will prolong the period of telemetry 
in patients who respond to the active treat- 
ment. 
A less radical means of achieving mono- 
therapy is by progressive withdrawal of co- 
medication. This is often done under open 
conditions in continuation studies of patients 
who have responded to the test drug in con- 
trolled trials. A more active approach to this 
design was adopted by Faught et a113 in a study 
of felbamate. Test medication was introduced 
and escalated over 1 week. Progressive re- 
duction of co-medication over 4 weeks was then 
immediately begun without awaiting a poss- 
ible response. Escape criteria were specified, 
requiring standard medication to be resumed if 
seizures increased to an unacceptable vel. A 
further unusual and possible controversial 
feature of this trial was the choice of control: 
sodium valproate in a low dose assumed to be 
subtherapeutic was used as a substitute for a 
placebo. This apparently was acceptable to the 
ethical review committee concerned, and 
indeed does not appear to involve any unac- 
ceptable risk to patients. However, as most of 
the patients receiving the low-dose 'active 
control' suffered an increase in seizures and 
escaped, it may be argued that the use of an 
inactive control would have been no less ac- 
ceptable and would have given a more easily 
interpretable result. In the event, 40% of 
patients escaped on felbamate and 78% on low- 
dose valproate, a result significantly in favour 
of the former (P < 0.001). 
Monotherapy trials are also feasible in 
newly diagnosed patients in whom there is 
arguably no absolute necessity for immediate 
effective treatment. The ethical considerations 
are, however, less straightforward than they 
might at first appear. It may be argued that 
patients who do not need antiepileptic treat- 
ment, particularly those who after a single 
seizure do not technically have epilepsy, 
should not be exposed to the risks, incon- 
venience and stigma of taking AEDs. Con- 
versely, there is an increasing body of evidence 
to suggest hat the long-term prognosis for ter- 
minal remission of newly diagnosed epilepsy is 
dependent on the speed with which treatment 
is started and seizures controlled. This may be 
taken to support an ethical case against start- 
ing treatment with a drug of uncertain effi- 
cacy. This argument does not preclude trials in 
newly diagnosed patients, but does suggest 
that they should not be undertaken until effi- 
cacy and safety are well established, i.e. in 
phase IV. Both of these different ethical argu- 
ments lead to the conclusion that early testing 
of new drugs for epilepsy is likely to remain 
confined to that minority of patients whose epi- 
lepsy is refractory to established medication, 
and that product licences for new AEDs will be 
correspondingly restricted. 
OUTCOME 
It is, perhaps belatedly, becoming increasingly 
realised that the needs of people with epilepsy 
are not met simply by control of seizures. An 
important consideration i marketing of AEDs 
is the recognition that some may offer con- 
siderable advantages over their competitors in 
terms of quality of life. 
Simultaneous recognition of both these prop- 
ositions has led to the inclusion of increasingly 
sophisticated quality of life measures among 
the outcome variables of AED trials. 
Seizure-related variables relate both to 
occurrence and severity of attacks. Occurrence 
is traditionally measured as frequency, but 
seizure-free days or inter-seizure interval may 
be more sensitive to therapeutic effect if 
attacks occur in clusters, and are indices more 
relevant o the disruption of the patient's life. 
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Because of the very large scatter of seizure 
frequencies between trial subjects, simple 
parametric statistics based on mean seizure 
frequency across patients may be less powerful 
than such methods as the sign test or the 
Wilcoxon signed ranks test, which can be used 
for within patients comparisons in crossover 
trials. The proportion of patients achieving a
50% seizure reduction is widely used as a 
measure of 'clinically significant' change. This 
measure is, however, probably overrated as a 
means of comparing trial outcomes; the 
'therapy-resistant pa ient' is not an inbred lab- 
oratory animal suitable for a standardized bio- 
assay, and the results depend on the degree of 
intractability displayed by the patients at 
different sites. It is indeed striking how consis- 
tent are the differences between major trial 
centres when investigating different AEDs. 
.Other seizure-related outcome measures 
worth considering include severity (seizure 
classification, falling and injury, loss of con- 
sciousness, confusion and automatism, inconti- 
nence, etc.) and the patient's perceived egree 
of control (time of occurrence, premonitory 
symptoms, predictability ofseizures). 
The development of non-seizure-related 
quality of life measures relevant to epilepsy is 
as yet in an early stage. Areas of concern 
include cognitive function, affect, impact on 
education and employment, friendship, family 
relations and psychosexual function, pos- 
session of a driving licence, restriction of 
activities, and the sense of stigmatization. 
Such measures are beginning to be used in 
AED trials and prove sensitive to the effects of 
treatment 14. 
CONCLUSION 
Whilst epileptologists can only welcome the de- 
velopment of drugs which are of benefit o the 
most seriously disadvantaged patients, there 
remains an urgent need for new, safe, less 
sedative, non-teratogenic agents to improve 
the quality of life for the much-larger majority 
of patients whose difficulties are not solved by 
seizure control alone. Improved rug develop- 
ment programmes to achieve arly registration 
for monotherapy in non-resistant patients 
have yet to be devised. 
REFERENCES 
1. Coatsworth, J.J. Studies on the Clinical Efficacy of 
Marketed Antiepileptic Drugs. NINDS Monograph no. 
12. Washington, USA, Government Printing Office, 
1971. 
2. Richens, A. Drug Treatment of Epilepsy. London, 
Kimpson, 1976. 
3. Gram, L., Drachman-Bentsen, K., Parnas, J. and 
Flachs, H. Controlled trials in epilepsy: a review. Epi- 
lepsia 1982; 23: 491-519. 
4. Overweg, J. and Binnie, C.D. Benzodiazepines in
neurological disorders. In: The Benzodiazepines: From 
Molecular Biology to Clinical Practice (Ed. E. Costa}. 
New York, USA, Raven Press, 1983: pp. 339-347. 
5. Patsalos, P.N., Shorvon, S.D., Elyas, A.A., Smith, G. 
The interaction of denzimol (a new anticonvulsant) 
with carbamazepine and phenytoin. Journal of Neurol- 
ogy, Neurosurgery and Psychiatry 1985; 48: 374-377. 
6. Treiman, D.M. and Ben-Menachem, E. Inhibition of 
carbamazepine anbd phenytoin metabolism by nafimi- 
done, a new antiepileptic drug. Epilepsia 1987; 28: 
699-705. 
7. Hansen, J.M., Kristensen, M. and Skovsted, L. Sul- 
thiame (Ospolot) as inhibitor of diphenylhydantoin 
metabolism. Epilepsia 1968; 9: 17-22. 
8. Binnie, C.D., Van Erode Boas, W., Kasteleijn-Nolst 
Trenit~, D.G.A. et al. Acute effect of lamotrigine 
(BW430C) in persons with epilepsy. Epilepsia 1986; 27: 
248-254. 
9. Leppik, I.E., Dreifuss, F.E., Pledger, G.W. et al. Felba- 
mate for partial seizures: results of a controlled clinical 
trial. Neurology 1991; 41: 1785-1789. 
10. Binnie, C.D., Debets, R., Engelsman, M. et al. Double- 
blind crossover trial of lamotrigine (Lamictai) as add- 
on therapy in intractable epilepsy. Epilepsy Research 
1989; 4: 222-229. 
11. Bourgeois, B., Leppik, I., Sackellares, J.C. et al. Felba- 
mate: a double-blind controlled trial in patients under- 
going presurgical evaluation of partial seizures. 
Neurology 1993; 43: 693-696. 
12. Alarcon, G., Binnie, C.D., Elwes, R.D.C. and Polkey, 
C.E. Remacemide monotherapy in patients undergoing 
acute antiepileptic drug withdrawal. Seizure 1992; 1 
(Suppl. A): 70-71. 
13. Faught, E., Sachdeo, R.C., Remler, M.P. et al. Felba- 
mate monotherapy for partial-onset seizures: an 
active-control trial. Neurology 1993; 43: 688-692. 
14. Smith, D., Baker, G., Davies, G., Yuen, W. and 
Chadwick, D. Randomized, placebo-controlled, double- 
blind, crossover trial of lamotrigine as add-on therapy 
in patients with refractory epilepsy. Epilepsia 1991; 32 
(Suppl. 1): 59. 
